



US007183256B2

(12) **United States Patent**
Anand-Apte

(10) **Patent No.:** **US 7,183,256 B2**
(45) **Date of Patent:** **Feb. 27, 2007**

- (54) **TIMP3 AS VEGF INHIBITOR**
- (75) Inventor: **Bela Anand-Apte**, Shaker Heights, OH (US)
- (73) Assignee: **Cleveland Clinic Foundation**, Cleveland, OH (US)
- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 167 days.
- (21) Appl. No.: **10/804,937**
- (22) Filed: **Mar. 19, 2004**
- (65) **Prior Publication Data**
US 2004/0224398 A1 Nov. 11, 2004

Related U.S. Application Data

- (60) Provisional application No. 60/456,768, filed on Mar. 21, 2003.
 - (51) **Int. Cl.**
A61K 38/17 (2006.01)
C07K 14/435 (2006.01)
 - (52) **U.S. Cl.** 514/12; 530/324; 530/350
 - (58) **Field of Classification Search** 514/12;
530/324, 350
- See application file for complete search history.

(56) **References Cited**

FOREIGN PATENT DOCUMENTS

WO	WO 95/05478 A1	2/1995
WO	WO 95/09918 A1	4/1995

OTHER PUBLICATIONS

Qi et al., ARVO Annual Meeting Abstract Search and Program Planner, Abstract No. 2753, May 5-10, 2002.*
Database NCBI Conserved Domain Search for Human TIMP3, printed on Oct. 28, 2005.

* cited by examiner

Primary Examiner—Jon Weber
Assistant Examiner—Rosanne Kosson
(74) *Attorney, Agent, or Firm*—Tarolli, Sundheim, Covell & Tummino LLP

(57) **ABSTRACT**

Polypeptides or proteins comprising tissue inhibitor of metalloproteinases-3 (TIMP3) or variants of TIMP3 can be used to substantially inhibit vascular endothelial growth factor (VEGF) binding to VEGF receptor-2 (VEGFR2/KDR/Flk-1)) without substantially inhibiting VEGF binding to VEGF receptor 1 (VEGFR1/Flt-1).

6 Claims, 8 Drawing Sheets

